BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
28 août 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
08 août 2024 16h05 HE
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H...
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
01 août 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
25 juil. 2024 17h39 HE
|
BioAtla, Inc.
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly...
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
23 juil. 2024 08h00 HE
|
BioAtla, Inc.
Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in...
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
27 juin 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies Global Healthcare Conference
29 mai 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23 mai 2024 17h05 HE
|
BioAtla, Inc.
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as...
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
14 mai 2024 16h05 HE
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for...
BioAtla to Participate in the Citizens JMP Life Sciences Conference
08 mai 2024 08h00 HE
|
BioAtla, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...